Parallax Volatility Advisers
PBYI icon

Parallax Volatility Advisers’s Puma Biotechnology PBYI Stock Holding History

Parallax Volatility Advisers’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-12,000
Closed -$105K – 2655
2019
Q4 		$105K Hold
12,000
– – ﹤0.01% 2130
2019
Q3 		$129K Buy
+12,000
New +$130K ﹤0.01% 1936

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Parallax Volatility Advisers's PBYI Position: Q1 2020 in Review

Parallax Volatility Advisers sold out of Puma Biotechnology (PBYI) in Q1 2020, closing a stake of 176 shares — an estimated $2K sold.

Parallax Volatility Advisers first reported a position in PBYI in Q3 2016 and held it in 7 quarters. The position peaked at $3.53M in Q2 2018. 125 funds tracked by Wall St. Rank hold PBYI as of Q1 2020.

  • Parallax Volatility Advisers reported no remaining Puma Biotechnology position as of Q1 2020 after selling out during the quarter.
  • Parallax Volatility Advisers sold 176 Puma Biotechnology shares in Q1 2020, an estimated $2K.
  • Parallax Volatility Advisers first reported a position in Puma Biotechnology in Q3 2016 and held it in 7 quarters.
  • Parallax Volatility Advisers's Puma Biotechnology position peaked at $3.53M in Q2 2018.
  • 125 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2020.

Based on Parallax Volatility Advisers's 13F filing for Q1 2020, filed 15 May 2020.